BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen Y, Zeng Q, Liu X, Fu J, Zeng Z, Zhao Z, Liu Z, Bai W, Dong Z, Liu H, Lu X, Zhu Y, Lu Y. LINE-1 ORF-1p enhances the transcription factor activity of pregnenolone X receptor and promotes sorafenib resistance in hepatocellular carcinoma cells. Cancer Manag Res 2018;10:4421-38. [PMID: 30349375 DOI: 10.2147/CMAR.S176088] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Kou Y, Wang S, Ma Y, Zhang N, Zhang Z, Liu Q, Mao Y, Zhou R, Yi D, Ma L, Zhang Y, Li Q, Wang J, Wang J, Zhou X, He C, Ding J, Cen S, Li X. A High Throughput Cell-Based Screen Assay for LINE-1 ORF1p Expression Inhibitors Using the In-Cell Western Technique. Front Pharmacol 2022;13:881938. [DOI: 10.3389/fphar.2022.881938] [Reference Citation Analysis]
2 Niu X, Wu T, Li G, Gu X, Tian Y, Cui H. Insights into the critical role of the PXR in preventing carcinogenesis and chemotherapeutic drug resistance. Int J Biol Sci 2022;18:742-59. [PMID: 35002522 DOI: 10.7150/ijbs.68724] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Luo M, Sun H, Jiang Q, Chai Y, Li C, Yang B, Hong Z. Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma. Front Oncol 2021;11:777356. [PMID: 34926286 DOI: 10.3389/fonc.2021.777356] [Reference Citation Analysis]
4 Shao QP, Wei C, Yang J, Zhang WZ. miR-3609 Decelerates the Clearance of Sorafenib in Hepatocellular Carcinoma Cells by Targeting EPAS-1 and Reducing the Activation of the Pregnane X Receptor Pathway. Onco Targets Ther 2020;13:7213-27. [PMID: 32801751 DOI: 10.2147/OTT.S246471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
5 Yu C, Wang Y, Liu T, Sha K, Song Z, Zhao M, Wang X. The microRNA miR-3174 Suppresses the Expression of ADAM15 and Inhibits the Proliferation of Patient-Derived Bladder Cancer Cells. Onco Targets Ther 2020;13:4157-68. [PMID: 32547057 DOI: 10.2147/OTT.S246710] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
6 Yang B, Wang C, Xie H, Wang Y, Huang J, Rong Y, Zhang H, Kong H, Yang Y, Lu Y. MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. Cell Death Dis 2019;10:784. [PMID: 31611551 DOI: 10.1038/s41419-019-2023-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 37] [Article Influence: 8.3] [Reference Citation Analysis]
7 Yin F, Feng F, Wang L, Wang X, Li Z, Cao Y. SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity. Cell Death Dis 2019;10:672. [PMID: 31511501 DOI: 10.1038/s41419-019-1884-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 55] [Article Influence: 10.0] [Reference Citation Analysis]
8 Hou FJ, Guo LX, Zheng KY, Song JN, Wang Q, Zheng YG. Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells. Onco Targets Ther 2019;12:6685-97. [PMID: 31695406 DOI: 10.2147/OTT.S215103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Gao X, Chen H, Huang X, Li H, Liu Z, Bo X. ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance. Onco Targets Ther 2019;12:1629-40. [PMID: 30881018 DOI: 10.2147/OTT.S196713] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
10 Honda T, Rahman MA. Profiling of LINE-1-Related Genes in Hepatocellular Carcinoma. Int J Mol Sci 2019;20:E645. [PMID: 30717368 DOI: 10.3390/ijms20030645] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]